semaglutide counterfeit FDA, Novo Nordisk warn of Ozempic on U.S. market Focus: Demand for weight-loss drugs

Individuals with a history of pancreatitis Individuals with kidney/liver problems 2

However, eligibility goes beyond just BMI

While initially developed as a medication to manage type 2 diabetes, clinical trials have demonstrated its effectiveness in promoting weight loss in people without diabetes who struggle with obesity or overweight

Editorial note This article reflects the independent clinical perspective and interpretation of current research by the author

According to the FDA prescribing information, these gastrointestinal symptoms are dose-dependent and represent the primary reason for treatment discontinuation in clinical trials